Jefferson Health in Philadelphia is suing Aetna over a new Medicare Advantage payment policy that hospitals say unfairly ...

For years, healthcare reform discussions have focused on insurance premiums, drug prices, and hospital consolidation. Yet one of the most consequential battles in healthcare is unfolding in a far ...

Generic medicines face no tariffs, though the Trump administration reserves the right to revisit that in the future. Some ...

Insmed’s new drug, Brinsupri, is still projected to reach blockbuster status, but an inflammatory skin disorder is no longer in the picture following a mid-stage clinical trial failure in this ...

A colorectal cancer blood test candidate from Exact Sciences fell short in its pivotal study, but the company is still in the hunt to provide an alternative to the liquid biopsy that was first to ...

Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...

Value-based care and Medicare Advantage are often heralded as two of healthcare’s most promising strategies for controlling costs, but industry leaders can’t quite tell if they’re actually working.

Neurocrine Biosciences is expanding its scope in rare endocrine disorders through the $2.9 billion acquisition of Soleno Therapeutics, a company that commercialized the first approved drug for a rare ...

Every year, thousands of Americans end up in emergency rooms for issues that could have been treated — and often prevented — in a dentist’s office. From a small cavity that goes unnoticed to severe ...

AI tools continue to flood the healthcare market, but not every startup will survive the hype cycle. Uma (Veerappan) Nuggehalli, a vice president at Flare Capital Partners, believes the companies ...

Editor’s Note: This roundup is meant to highlight some of the most notable funding rounds of the month and is not intended to be comprehensive. Health tech companies made several major funding ...